On Thursday, Biological E said that it will submit final data for its Covid-19 vaccine Corbevax until the end of November. The news comes only two days after the big pharmaceutical firm applied to the Drugs Controller General of India for permission to start a phase 3 clinical study of the Covid vaccine Corbevax. For people who have been completely vaccinated with Covishield or Covaxin vaccinations, the firm has applied for clearance as a single booster dosage.
The Central Drugs Standard Control Organisation (CDSCOSubject )’s Expert Committee (SEC) on COVID-19 may examine the issue at its next meeting.
The phase 2/3 clinical trials of Corbevax are underway and the results are likely to be declared this month.
Corbevax is based on a protein antigen technology that binds to the Angiotensin Converting Enzyme-2 (ACE2) receptor on the host cell membrane and facilitates virus entry. The body’s own cells stimulate the immune system of the body to produce antibodies to protect against the infection.
